tetano
Editor, Senior Moderator
Clin Immunol
. 2022 Aug 29;243:109106.
doi: 10.1016/j.clim.2022.109106. Online ahead of print.
SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children
Ki Pui Lam[SUP] 1 [/SUP], Marcos Chiñas[SUP] 2 [/SUP], Amélie M Julé[SUP] 3 [/SUP], Maria Taylor[SUP] 1 [/SUP], Marina Ohashi[SUP] 4 [/SUP], Mehdi Benamar[SUP] 1 [/SUP], Elena Crestani[SUP] 1 [/SUP], Mary Beth F Son[SUP] 1 [/SUP], Janet Chou[SUP] 1 [/SUP], Catherine Gebhart[SUP] 4 [/SUP], Talal Chatila[SUP] 1 [/SUP], Jane Newburger[SUP] 5 [/SUP], Adrienne Randolph[SUP] 6 [/SUP], Maria Gutierrez-Arcelus[SUP] 2 [/SUP], Lauren A Henderson[SUP] 7 [/SUP]
Affiliations
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infections that occurs in the pediatric population. We sought to characterize T cell responses in MIS-C compared to COVID-19 and pediatric hyperinflammatory syndromes. MIS-C was distinct from COVID-19 and hyperinflammatory syndromes due to an expansion of T cells expressing TRBV11-2 that was not associated with HLA genotype. Children diagnosed with MIS-C, but who were negative for SARS-CoV-2 by PCR and serology, did not display Vβ skewing. There was no difference in the proportion of T cells that became activated after stimulation with SARS-CoV-2 peptides in children with MIS-C compared to convalescent COVID-19. The frequency of SARS-CoV-2-specific TCRs and the antigens recognized by these TCRs were comparable in MIS-C and COVID-19. Expansion of Vβ11-2[SUP]+[/SUP] T cells was a specific biomarker of MIS-C patients with laboratory confirmed SARS-CoV-2 infections. Children with MIS-C had robust antigen-specific T cell responses to SARS-CoV-2.
Keywords: Coronavirus disease 2019 (COVID-19); Multisystem inflammatory syndrome in children (MIS-C); Pediatrics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); T cell receptor (TCR) repertoire.
. 2022 Aug 29;243:109106.
doi: 10.1016/j.clim.2022.109106. Online ahead of print.
SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children
Ki Pui Lam[SUP] 1 [/SUP], Marcos Chiñas[SUP] 2 [/SUP], Amélie M Julé[SUP] 3 [/SUP], Maria Taylor[SUP] 1 [/SUP], Marina Ohashi[SUP] 4 [/SUP], Mehdi Benamar[SUP] 1 [/SUP], Elena Crestani[SUP] 1 [/SUP], Mary Beth F Son[SUP] 1 [/SUP], Janet Chou[SUP] 1 [/SUP], Catherine Gebhart[SUP] 4 [/SUP], Talal Chatila[SUP] 1 [/SUP], Jane Newburger[SUP] 5 [/SUP], Adrienne Randolph[SUP] 6 [/SUP], Maria Gutierrez-Arcelus[SUP] 2 [/SUP], Lauren A Henderson[SUP] 7 [/SUP]
Affiliations
- PMID: 36049601
- PMCID: PMC9423880
- DOI: 10.1016/j.clim.2022.109106
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infections that occurs in the pediatric population. We sought to characterize T cell responses in MIS-C compared to COVID-19 and pediatric hyperinflammatory syndromes. MIS-C was distinct from COVID-19 and hyperinflammatory syndromes due to an expansion of T cells expressing TRBV11-2 that was not associated with HLA genotype. Children diagnosed with MIS-C, but who were negative for SARS-CoV-2 by PCR and serology, did not display Vβ skewing. There was no difference in the proportion of T cells that became activated after stimulation with SARS-CoV-2 peptides in children with MIS-C compared to convalescent COVID-19. The frequency of SARS-CoV-2-specific TCRs and the antigens recognized by these TCRs were comparable in MIS-C and COVID-19. Expansion of Vβ11-2[SUP]+[/SUP] T cells was a specific biomarker of MIS-C patients with laboratory confirmed SARS-CoV-2 infections. Children with MIS-C had robust antigen-specific T cell responses to SARS-CoV-2.
Keywords: Coronavirus disease 2019 (COVID-19); Multisystem inflammatory syndrome in children (MIS-C); Pediatrics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); T cell receptor (TCR) repertoire.